Abstract:Background: Numerous studies have demonstrated that iron overload is a risk factor of osteoporosis. However, there has been no systematic and in-depth studies on the effect of iron overload on osteocytes and its role in iron overload-induced bone loss. Therefore, to address this problem, we carried out in vitro and in vivo studies using MLO-Y4 osteocyte-like cells and Hepcidin(-/-) mice as iron overload models. Methods: (1) MLO-Y4 cells were treated with ferric ammonium citrate (FAC). Intracellular reactive oxygen species (ROS) levels and apoptosis of MLO-Y4 cells were determined by flow cytometry. Western blotting was performed to evaluate the effect of FAC on the expression of sclerostin and RANKL/OPG. (2) The conditioned medium of MLO-Y4 cells after treatment with FAC was collected and used to treat pre-osteoblasts and monocytes. Alkaline phosphatase (ALP) staining and alizarin red (AR) staining were used to evaluate osteogenic differentiation capacity, and tartrate-resistant acid phosphatase (TRAP) staining was performed to demonstrate osteoclast differentiation capacity. (3) In vivo studies included a wild type mouse, Hepcidin(-/-) mice, Hepcidin(-/-) mice + deferoxamine (DFO), and Hepcidin(-/-) mice + N-actyl-L-cysteine (NAC) group. Micro-CT was performed to evaluate the bone mineral density (BMD), bone volume, and bone micro-architecture of the mice, and three bending tests were used to assess bone strength. Histological analysis was used to detect alterations in bone turnover. TUNEL staining and scanning electron microscopy (SEM) were performed to evaluate the apoptosis and morphology of osteocytes. Immunohistochemical staining and Western blotting were used to determine alterations in sclerostin and RANKL/OPG expression levels in mice. Results: (1) FAC increased intracellular ROS and apoptosis in MLO-Y4 cells, while FAC enhanced the expression of sclerostin and RANKL/OPG in MLO-Y4 cells. (2) Conditioned medium of MLO-Y4 cells inhibited the osteogenic capacity of osteoblasts while stimulating osteoclast differentiation. (3) By increasing oxidative stress, iron overload promotes the apoptosis of osteocytes and undermines the morphology of osteocytes in Hepcidin(-/-) mice, further increasing the expression levels of sclerostin and RANKL/OPG in osteocytes, which is considered to be the causative factor for reduced bone formation and enhanced bone resorption. DFO administration reduced iron levels, and NAC treatment decreased oxidative stress in Hepcidin(-/-) mice. Therefore, DFO or NAC treatment rescued the decrease in BMD, bone volume, and bone strength and attenuated the deterioration of bone architecture in Hepcidin(-/-) mice by attenuating the effect of iron overload on osteocytes. Conclusion: Osteocyte apoptosis due to increased ROS and resultant sclerostin and RANKL/OPG expression alteration was the main reason for bone loss in Hepcidin(-/-) mice. Osteocytes are the main targets for the prevention and treatment of iron overload-induced osteoporosis.

Iron-dependent KDM4D activity controls the quiescence-activity balance of MSCs via the PI3K-Akt-Foxo1 pathway

Iron accumulation induces reactive oxide species to inhibits mesenchymal stem cells and osteogenesis via nicotinamide adenine dinucleotide phosphate reduced oxidase 4 activation

Iron Accumulation Leads to Bone Loss by Inducing Mesenchymal Stem Cell Apoptosis Through the Activation of Caspase3

Loss of KDM4B exacerbates bone-fat imbalance and mesenchymal stromal cell exhaustion in skeletal aging

Iron overload promotes mitochondrial fragmentation in mesenchymal stromal cells from myelodysplastic syndrome patients through activation of the AMPK/MFF/Drp1 pathway

Effects of iron overload on the bone marrow microenvironment in mice.

Iron Overload Injures the Function of MDS-Derived Mesenchymal Stromal Cells through Activating the Ampkα/Mff/Drp1 Signaling Pathway

Iron deficiency–induced ferritinophagy impairs skeletal muscle regeneration through RNF20-mediated H2Bub1 modification

Histone Demethylases KDM4B and KDM6B Promotes Osteogenic Differentiation of Human MSCs.

Iron Overload Threatens the Growth of Osteoblast Cells Via Inhibiting the PI3K/AKT/FOXO3a/DUSP14 Signaling Pathway.

Iron-dependent Histone 3 Lysine 9 Demethylation Controls B Cell Proliferation and Humoral Immune Responses

Iron Overload Induced Osteocytes Apoptosis and Led to Bone Loss in Hepcidin−/− Mice Through Increasing Sclerostin and RANKL/OPG

Effect of Iron Deficiency on C-Kit(+) Cardiac Stem Cells in Vitro

Deferoxamine Inhibits Iron-Uptake Stimulated Osteoclast Differentiation by Suppressing Electron Transport Chain and MAPKs Signaling.

Iron overload inhibits osteogenesis and promotes adipogenesis in human bone marrow mesenchymal stem cells by producing reactive oxygen

Iron accumulation induces bone marrow mesenchymal stem cells apoptosis via cysteinyl-aspartate-specific proteases-3 activation and inhibits osteogenesis

Differential Iron Requirements for Osteoblast and Adipocyte Differentiation

Iron Overload Impairs Normal Hematopoietic Stem and Progenitor Cells Through Reactive Oxygen Species and Shortens Survival in Myelodysplastic Syndrome Mice

Melatonin Protects Bone Marrow Mesenchymal Stem Cells Against Iron Overload‐induced Aberrant Differentiation and Senescence

SIRT6 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells Through BMP Signaling.

Iron Homeostasis Determines Fate of Human Pluripotent Stem Cells Via Glycerophospholipids-Epigenetic Circuit.